The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | EP0042, an inhibitor of FLT3 & Aurora kinases, in R/R AML and MDS: insights from a Phase I/IIa trial
David Taussig, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, presents the findings of a Phase I/IIa trial investigating EP0042, an orally bioavailable potent inhibitor of FLT3 and Aurora kinases, as a treatment for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Dr Taussig discusses data from the study’s dose-finding and dose-optimization cohorts, outlining the safety and efficacy of the agent. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Ellipses Pharma
